Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

S.-B. Kim; D.J. Maslyar; R. Dent; S.-A. Im; M. Espié; S. Blau; A.R. Tan; S. Isakoff; M. Oliveira; C. Saura; M.J. Wongchenko; A.V. Kapp; W.Y. Chan; S.M. Singel; J. Baselga; S.-B. Kim; K.S. Lee; S.-A. Im; M. Espié; H.-C. Wang; S. Blau; R. Dent; A. Tan; J.H. Sohn; M. De Laurentiis; L.G. Estevez; C.-S. Huang; G. Romieu; M. Velez; R. Villanueva; P.F. Conte; S. Dakhil; M. Debled; A.G. Martin; S. Hurvitz; J.H. Kim; C. Levy; M. Oliveira; P.S. Rovira; J.H. Seo; V. Valero; G. Vidal; A. Wong; M.A.K. Allison; R. Figlin; D. Chan; S.-C. Chen; Y.-H. Chen; M. Cobleigh; F. De Braud; L. Dirix; V. Hansen; A.H. Bessard; N. Iannotti; S. Isakoff; W. Lawler; A. Montaño; M. Salkini; L. Seigel

doi:10.1016/S1470-2045(17)30450-3

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

S.-B. Kim, D.J. Maslyar, R. Dent, S.-A. Im, M. Espié, S. Blau, A.R. Tan, S. Isakoff, M. Oliveira, C. Saura, M.J. Wongchenko, A.V. Kapp, W.Y. Chan, S.M. Singel, J. Baselga, S.-B. Kim, K.S. Lee, S.-A. Im, M. Espié, H.-C. WangS. Blau, R. Dent, A. Tan, J.H. Sohn, M. De Laurentiis, L.G. Estevez, C.-S. Huang, G. Romieu, M. Velez, R. Villanueva, P.F. Conte, S. Dakhil, M. Debled, A.G. Martin, S. Hurvitz, J.H. Kim, C. Levy, M. Oliveira, P.S. Rovira, J.H. Seo, V. Valero, G. Vidal, A. Wong, M.A.K. Allison, R. Figlin, D. Chan, S.-C. Chen, Y.-H. Chen, M. Cobleigh, F. De Braud, L. Dirix, V. Hansen, A.H. Bessard, N. Iannotti, S. Isakoff, W. Lawler, A. Montaño, M. Salkini, L. Seigel

Research output: Contribution to journal › Article › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1360-1372
Number of pages	13
Journal	The Lancet Oncology
Volume	18
Issue number	10
DOIs	https://doi.org/10.1016/S1470-2045(17)30450-3
Publication status	Published - 2017

Access to Document

10.1016/S1470-2045(17)30450-3

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85027258099&doi=10.1016%2fS1470-2045%2817%2930450-3&partnerID=40&md5=40dedf22416e8a0796d241d2dc688050

Cite this

Kim, S-B., Maslyar, D. J., Dent, R., Im, S-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S., Oliveira, M., Saura, C., Wongchenko, M. J., Kapp, A. V., Chan, W. Y., Singel, S. M., Baselga, J., Kim, S-B., Lee, K. S., Im, S-A., Espié, M., ... Seigel, L. (2017). Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology, 18(10), 1360-1372. https://doi.org/10.1016/S1470-2045(17)30450-3

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. / Kim, S.-B.; Maslyar, D.J.; Dent, R. et al.

In: The Lancet Oncology, Vol. 18, No. 10, 2017, p. 1360-1372.

Research output: Contribution to journal › Article › peer-review

Kim, S-B, Maslyar, DJ, Dent, R, Im, S-A, Espié, M, Blau, S, Tan, AR, Isakoff, S, Oliveira, M, Saura, C, Wongchenko, MJ, Kapp, AV, Chan, WY, Singel, SM, Baselga, J, Kim, S-B, Lee, KS, Im, S-A, Espié, M, Wang, H-C, Blau, S, Dent, R, Tan, A, Sohn, JH, De Laurentiis, M, Estevez, LG, Huang, C-S, Romieu, G, Velez, M, Villanueva, R, Conte, PF, Dakhil, S, Debled, M, Martin, AG, Hurvitz, S, Kim, JH, Levy, C, Oliveira, M, Rovira, PS, Seo, JH, Valero, V, Vidal, G, Wong, A, Allison, MAK, Figlin, R, Chan, D, Chen, S-C, Chen, Y-H, Cobleigh, M, De Braud, F, Dirix, L, Hansen, V, Bessard, AH, Iannotti, N, Isakoff, S, Lawler, W, Montaño, A, Salkini, M & Seigel, L 2017, 'Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial', The Lancet Oncology, vol. 18, no. 10, pp. 1360-1372. https://doi.org/10.1016/S1470-2045(17)30450-3

@article{13bab4be1c064f61a91a48016293bc28,

title = "Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial",

author = "S.-B. Kim and D.J. Maslyar and R. Dent and S.-A. Im and M. Espi{\'e} and S. Blau and A.R. Tan and S. Isakoff and M. Oliveira and C. Saura and M.J. Wongchenko and A.V. Kapp and W.Y. Chan and S.M. Singel and J. Baselga and S.-B. Kim and K.S. Lee and S.-A. Im and M. Espi{\'e} and H.-C. Wang and S. Blau and R. Dent and A. Tan and J.H. Sohn and {De Laurentiis}, M. and L.G. Estevez and C.-S. Huang and G. Romieu and M. Velez and R. Villanueva and P.F. Conte and S. Dakhil and M. Debled and A.G. Martin and S. Hurvitz and J.H. Kim and C. Levy and M. Oliveira and P.S. Rovira and J.H. Seo and V. Valero and G. Vidal and A. Wong and M.A.K. Allison and R. Figlin and D. Chan and S.-C. Chen and Y.-H. Chen and M. Cobleigh and {De Braud}, F. and L. Dirix and V. Hansen and A.H. Bessard and N. Iannotti and S. Isakoff and W. Lawler and A. Monta{\~n}o and M. Salkini and L. Seigel",

note = "cited By 5",

year = "2017",

doi = "10.1016/S1470-2045(17)30450-3",

language = "Non definita",

volume = "18",

pages = "1360--1372",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "10",

}

TY - JOUR

T1 - Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

AU - Kim, S.-B.

AU - Maslyar, D.J.

AU - Dent, R.

AU - Im, S.-A.

AU - Espié, M.

AU - Blau, S.

AU - Tan, A.R.

AU - Isakoff, S.

AU - Oliveira, M.

AU - Saura, C.

AU - Wongchenko, M.J.

AU - Kapp, A.V.

AU - Chan, W.Y.

AU - Singel, S.M.

AU - Baselga, J.

AU - Kim, S.-B.

AU - Lee, K.S.

AU - Im, S.-A.

AU - Espié, M.

AU - Wang, H.-C.

AU - Blau, S.

AU - Dent, R.

AU - Tan, A.

AU - Sohn, J.H.

AU - De Laurentiis, M.

AU - Estevez, L.G.

AU - Huang, C.-S.

AU - Romieu, G.

AU - Velez, M.

AU - Villanueva, R.

AU - Conte, P.F.

AU - Dakhil, S.

AU - Debled, M.

AU - Martin, A.G.

AU - Hurvitz, S.

AU - Kim, J.H.

AU - Levy, C.

AU - Oliveira, M.

AU - Rovira, P.S.

AU - Seo, J.H.

AU - Valero, V.

AU - Vidal, G.

AU - Wong, A.

AU - Allison, M.A.K.

AU - Figlin, R.

AU - Chan, D.

AU - Chen, S.-C.

AU - Chen, Y.-H.

AU - Cobleigh, M.

AU - De Braud, F.

AU - Dirix, L.

AU - Hansen, V.

AU - Bessard, A.H.

AU - Iannotti, N.

AU - Isakoff, S.

AU - Lawler, W.

AU - Montaño, A.

AU - Salkini, M.

AU - Seigel, L.

N1 - cited By 5

PY - 2017

Y1 - 2017

U2 - 10.1016/S1470-2045(17)30450-3

DO - 10.1016/S1470-2045(17)30450-3

M3 - Articolo

VL - 18

SP - 1360

EP - 1372

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 10

ER -